Back to Search
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
Peoria, Illinois, 61614
Chandler, Arizona, 85224
Austin, Texas, 78705
San Diego, California, 92108
Melbourne, Florida, 32934
Chandler, Arizona, 85224
Austin, Texas, 78705
San Diego, California, 92108
Melbourne, Florida, 32934
Search ended 04/12/2022
The primary goal for this study is to evaluate the safety and reactogenicity of 3 dose levels of mRNA-1283 and 1 dose level of mRNA-1273 vaccine given to healthy adults in 2 doses, 28 days apart, and 1 dose level of mRNA-1283 administered as a single dose to healthy adults.
Eligibility
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, learn about Clinical
| Ages Eligible for Study | Min Age: 18 years - Max Age: 55 years |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
Visit ClinicalTrials.Gov for more information
Support nonprofit organizations through participating in clinical trials at no cost to you
You may also be interested in
River Forest, Illinois and more
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
Herpes Zoster Read more
Hollywood, Florida and more
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-Year-Old Healthy Adults
Epstein-Barr Virus Infection Read more
Palo Alto, California and more